Aerie Pharma Receives a Buy from Needham

By Jason Carr

In a report issued on September 15, Alan Carr from Needham reiterated a Buy rating on Aerie Pharma (NASDAQ: AERI), with a price target of $65. The company’s shares closed on Friday at $58.30, close to its 52-week high of $60.15.

According to TipRanks.com, Carr is a 4-star analyst with an average return of 7.3% and a 44.3% success rate. Carr covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co Ltd, ACADIA Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.

Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $73.80, representing a 26.6% upside.

In a report issued on September 6, Mizuho Securities also initiated coverage with a Buy rating on the stock.

The company has a one year high of $60.15 and a one year low of $32.05. Currently, Aerie Pharma has an average volume of 455K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. It focuses on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company’s product candidates are Rhopressa and Roclatan. Aerie Pharmaceuticals was founded by David L. Epstein, Casey C.